9805434
IPOS

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 261/20, 231/56, A61K 31/42, 31/415

A1

(11) International Publication Number: WO 97/40027

(43) International Publication Date: 30 October 1997 (30.10.97)

(21) International Application Number: PCT/EP97/01904

(22) International Filing Date: 15 April 1997 (15.04.97)

(30) Priority Data:
96201068.8 19 April 1996 (19.04.96) EP
(34) Countries for which the regional or international application was filed: NL et al.

(71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).

(72) Inventors; and
(75) Inventors/Applicants (for US only): LEYSEN, Dirk, Casimir, Maria [BE/BE]; Kerkstraat 26, B-3920 Lommel (BE). RUIGT, Gerardus, Stephanus, Franciscus [NL/NL]; Monsterstraat 6, NL-5314 EB Oss (NL). LINDERS, Joannes, Theodorus, Maria [NL/NL]; Wagenaarstraat 309, NL-5343 CH Oss (NL). DIJCKS, Fredericus, Antonius [NL/NL]; Drijvershof 38, NL-5343 XB Oss (NL). GROVE, Simon, James, Anthony [GB/GB]; Flat 2/1, 21 Thornwood Avenue, Glasgow G11 7PH (GB). RAE, Duncan, Robertson [GB/GB]; 17 Cleghorn Road, Lanark, Lanarkshire ML11 7QR (GB).

(74) Agent: HERMANS, Franciscus, G., M.; P.O. Box 20, NL-5340 BH Oss (NL).


(81) Designated States: AU, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RU, SG, TR, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION

(57) Abstract

The present invention relates to certain novel benzylamine derivatives of formula (I) wherein R^1 and R^2, which may be the same or different, are each selected from C_{6-12}aryl, C_{2-14}heteroaryl, C_{6-12}arylC_{1-6}alkyl, C_{2-14}heteroarylC_{1-6}alkyl (where the alkyl, aryl or heteroaryl moiety may be optionally substituted by one or more substituents selected from C_{1-6}alkoxy, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{4-6}cycloalkenyl, C_{6-12}aryl, C_{2-14}heteroaryl, halogen, amino, hydroxy, haloC_{1-6}alkyl, nitro, C_{1-6}alkylthio, sulphonamide, C_{1-6}alkylsulphonyl, hydroxy-C_{1-6}alkyl, C_{1-6}alkoxycarbonyl, carboxyl, carboxyC_{1-6}alkyl, carboxamide and C_{1-6}alkylcarboxamide), hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{4-6}cycloalkenyl, C_{2-6}alkenyl, C_{2-6}alkynyl and C_{1-6}alkoxyC_{1-6}alkyl (where the alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, or alkoxyalkyl moieties may be optionally substituted by one or more substituents selected from amino, halogen, hydroxy, C_{1-6}alkylcarboxamide, carboxamide, carboxy, C_{1-6}alkoxycarbonyl, C_{1-6}alkylcarboxy and carboxyC_{1-6}alkyl) or one of R^1 and R^2 are as hereinbefore defined and one is hydroxy; R^3 and R^4, which may be the same or different, are each selected from C_{6-12}aryl, C_{2-14}heteroaryl, C_{6-12}arylC_{1-6}alkyl, C_{2-14}heteroarylC_{1-6}alkyl (where the alkyl, aryl or heteroaryl moiety may be optionally substituted by one or more substituents selected from C_{1-6}alkoxy, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{4-6}cycloalkenyl, C_{6-12}aryl, C_{2-14}heteroaryl, halogen, amino, hydroxy, haloC_{1-6}alkyl, nitro, C_{1-6}alkylthio, sulphonamide, C_{1-6}alkylsulphonyl, hydroxyC_{1-6}alkyl, C_{1-6}alkoxycarbonyl, carboxyl, carboxyC_{1-6}alkyl, C_{1-6}alkylcarboxamide and carboxamide), hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-6}alkyl, C_{4-6}cycloalkenyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy-C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{2-6}alkenyl, haloC_{2-6}alkynyl, cyano, carboxyl, C_{1-6}alkylcarboxy and carboxyC_{1-6}alkyl (where the alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, or alkoxyalkyl moieties may be optionally substituted by one or more substituents selected from amino, hydroxy, C_{1-6}alkylcarboxamide, carboxamide, carboxy, C_{1-6}alkoxycarbonyl, C_{1-6}alkylcarboxy and carboxyC_{1-6}alkyl); or one of R^3 or R^4 together with one of R^1 or R^2 and the N atom to which it is attached form a 5- or 6-membered heterocyclic ring. R^5 represents one or more ring substituents selected from halogen, hydrogen C_{1-6}alkyl and C_{1-6}alkoxy; and R^6 represents a single ring substituent of formula (A) wherein the dotted line represents an optional bond; Y is oxygen or -NR^8 (where R^8 is hydrogen or C_{1-6}alkyl) and R^7 represents one or more substituents selected from hydrogen, halogen, haloC_{1-6}alkyl, C_{1-6}alkyl and C_{1-6}alkoxy; or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment of depression.



(I)



(A)